New concepts of biobanks--strategic chance for uro-oncology.

Cancer, as well as other common diseases, is a complex condition that not only causes a major threat to human health, but also represents a huge burden to society in terms of healthcare cost and loss of economic productivity. Treatment improvements remain elusive, since the causes of cancer are due to a huge number of small and possibly additive effects arising from genetic susceptibility, lifestyle, and environmental conditions. Thus, progress in translational cancer research investigating these changes and their complex interaction is highly dependent on large series of cases (affected and unaffected individuals) including high quality samples and their associated data. Therefore, large and well-organized biobanks have been established, are underway, or are planned in many countries and institutions. The integration of these resources with powerful molecular and "omics" approaches, integrated bioinformatic tools hold the promise to further advance our knowledge of disease development, thus leading to better prevention and treatment strategies. However, these valuable and irreplaceable collections typically suffer from underutilization, due to fragmentation of the collections and their accessibility, lack of common management strategies, including consensus on standard operating procedures, unique policies of utilization, and distribution as well as missing input on a broad basis reflecting research needs on an interdisciplinary, multi-institutional fashion beyond project-driven interest. The uro-oncologic community has not yet contributed to these efforts to its full potential, and broad knowledge on the contemporary developments in the field of biobanking and input into these efforts are still missing. This review presents an overview on biobanking and may serve as an update to be integrated into future discussions on managing biobanks involving uro-oncology. It is based on the discussions at the last meeting of the International Bladder Cancer Network in Barcelona (Spain) in fall 2008 and has been also largely influenced by the works and discussions of the Marble Arch International Working Group on Biobanking for Biomedical Research.

[1]  Ronglai Shen,et al.  Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. , 2002, The American journal of pathology.

[2]  E. de Álava,et al.  Biobanking: old activity or young discipline? , 2008, Seminars in diagnostic pathology.

[3]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[4]  Thomas Burke,et al.  Human Biospecimen Research: Experimental Protocol and Quality Control Tools , 2009, Cancer Epidemiology Biomarkers & Prevention.

[5]  F. Liedberg,et al.  The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. , 2008, European urology.

[6]  Fay Betsou,et al.  Biobanking for better healthcare , 2008, Molecular oncology.

[7]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[8]  A. L. Bosch,et al.  Improvement of European translational cancer research. Collaboration between comprehensive cancer centers. , 2008, Tumori.

[9]  P J Drew,et al.  Prognostic factors: guidelines for investigation design and state of the art analytical methods. , 1998, Surgical oncology.

[10]  B. Knoppers,et al.  Trends in ethical and legal frameworks for the use of human biobanks , 2007, European Respiratory Journal.

[11]  Anirban P. Mitra,et al.  Molecular markers for bladder cancer: the road to a multimarker approach , 2007, Expert review of anticancer therapy.

[12]  Danielle Posthuma,et al.  Netherlands Twin Register: From Twins to Twin Families , 2006, Twin Research and Human Genetics.

[13]  L. Palmer UK Biobank: bank on it , 2007, The Lancet.

[14]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  A. L. Bosch,et al.  OECI TuBaFrost tumor biobanking. , 2008, Tumori.

[16]  Katherine C Sexton,et al.  Development of the ISBER Best Practices for Repositories: Collection, Storage, Retrieval and Distribution of Biological Materials for Research. , 2012, Biopreservation and biobanking.

[17]  P. Riegman,et al.  Standard operating procedure for the collection of fresh frozen tissue samples. , 2007, European journal of cancer.

[18]  E. de Álava,et al.  Tumour Banking: The Spanish Design , 2007, Pathobiology.

[19]  P. Riegman,et al.  Biobanking for Interdisciplinary Clinical Research , 2007, Pathobiology.

[20]  F. Betsou,et al.  Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. , 2008, Cytokine.

[21]  Paul Elliott,et al.  The UK Biobank sample handling and storage validation studies. , 2008, International journal of epidemiology.

[22]  A. Vlahou,et al.  Establishment of a European Network for Urine and Kidney Proteomics. , 2008, Journal of proteomics.

[23]  W. L. McGuire,et al.  Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.

[24]  S. Groshen,et al.  Guidelines for development of diagnostic markers in bladder cancer , 2008, World Journal of Urology.

[25]  Lennart Martens,et al.  ms_lims, a simple yet powerful open source laboratory information management system for MS‐driven proteomics , 2010, Proteomics.

[26]  I. Jurisica,et al.  Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. , 2004, Neoplasia.

[27]  D. Troyer,et al.  Biorepository standards and protocols for collecting, processing, and storing human tissues. , 2008, Methods in molecular biology.

[28]  M. Droller BLADDER, PENIS AND URETHRAL CANCER, AND BASIC PRINCIPLES OF ONCOLOGY , 2001 .

[29]  Designing and implementing a large-scale automated -80 degrees C archive. , 2008, International journal of epidemiology.

[30]  J. Ioannidis,et al.  Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. , 2007, Journal of the National Cancer Institute.

[31]  Akira Kurihara,et al.  The Hawaiian Algal Database: a laboratory LIMS and online resource for biodiversity data , 2009, BMC Plant Biology.

[32]  Richard P. Hill,et al.  The Basic Science of Oncology , 1989 .

[33]  T. Pretlow,et al.  Providing human tissues for research: how to establish a program. , 1998, Archives of pathology & laboratory medicine.

[34]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[35]  D. Sargent,et al.  Statistical issues in tumor marker studies. , 2000, Archives of pathology & laboratory medicine.

[36]  Design and implementation of a large-scale liquid nitrogen archive. , 2008, International journal of epidemiology.

[37]  H. Juhl,et al.  Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. , 2004, BioTechniques.

[38]  T. Tzai,et al.  Does HER2 Immunoreactivity Provide Prognostic Information in Locally Advanced Urothelial Carcinoma Patients Receiving Adjuvant M-VEC Chemotherapy? , 2007, Urologia Internationalis.

[39]  P. Elliott,et al.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.

[40]  J. Morote Robles [What...about tumor markers]. , 1988, Actas urologicas espanolas.

[41]  A. Steinfeld,et al.  The Basic Science of Oncology. 2nd ed , 1994 .

[42]  C. Begg,et al.  Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. , 2000, Statistics in medicine.

[43]  A. Merseburger,et al.  Deutscher Forschungsverbund Blasenkarzinom e.V. , 2008, Der Urologe.

[44]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[45]  Aza Mohammed,et al.  Biological markers in the diagnosis of recurrent bladder cancer: an overview , 2008, Expert review of molecular diagnostics.

[46]  S. Groshen,et al.  Special Communication , 2004 .

[47]  M. Knowles Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target , 2007, World Journal of Urology.

[48]  S. D. Sales,et al.  Designing an automated blood fractionation system. , 2008, International journal of epidemiology.

[49]  Rajiv Dhir,et al.  An informatics model for tissue banks – Lessons learned from the Cooperative Prostate Cancer Tissue Resource , 2006, BMC Cancer.

[50]  Nicky Best,et al.  Health impacts of long-term exposure to disinfection by-products in drinking water in Europe: HIWATE. , 2009, Journal of water and health.

[51]  F. Radvanyi,et al.  Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. , 2004, Analytical biochemistry.

[52]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[53]  Gabriela Bindea,et al.  iLAP: a workflow-driven software for experimental protocol development, data acquisition and analysis , 2009, BMC Bioinformatics.

[54]  Laura Sacha,et al.  Bank on it. , 2012, Mental health today.

[55]  Evert-Ben van Veen,et al.  Tumour banks: well-guarded treasures in the interest of patients , 2003, Nature Reviews Cancer.

[56]  M M Morente,et al.  TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. , 2006, European journal of cancer.

[57]  N. Malats,et al.  Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. , 2003, European urology.

[58]  M. Droller Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. , 2001, The Journal of urology.

[59]  J Quackenbush,et al.  Effects of ischemia on gene expression. , 2001, The Journal of surgical research.

[60]  G. Radda,et al.  The need for independent scientific peer review of Biobank UK , 2002, The Lancet.

[61]  Fotini Betsou,et al.  Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation , 2007, Clinical chemistry and laboratory medicine.

[62]  R. Chadwick,et al.  The Icelandic database—do modern times need modern sagas? , 1999, BMJ.

[63]  F. Pontén,et al.  Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens , 2006, Laboratory Investigation.

[64]  Susan Groshen,et al.  Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  L. Hertle,et al.  VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. , 2007, Anticancer research.

[66]  P. Lichtenstein,et al.  The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies , 2002, Journal of internal medicine.

[67]  T. Peakman,et al.  Design and implementation of a high-throughput biological sample processing facility using modern manufacturing principles. , 2008, International journal of epidemiology.

[68]  Martin Eisenacher,et al.  Using Laboratory Information Management Systems as central part of a proteomics data workflow , 2010, Proteomics.

[69]  Grossman,et al.  The First and Second International Workshops on Diagnostic and Prognostic Markers in Bladder Cancer. , 2000, Urologic oncology.

[70]  B. Kramer,et al.  Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M T Landi,et al.  Sample collection, processing and storage. , 1997, IARC scientific publications.

[72]  T M Luider,et al.  Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. , 2005, European urology.

[73]  M Schumacher,et al.  Sample size considerations for the evaluation of prognostic factors in survival analysis. , 2000, Statistics in medicine.

[74]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[75]  H. Wallace The need for independent scientific peer review of Biobank UK. , 2002, The Lancet.

[76]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[77]  John K Gohagan,et al.  The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. , 2004, Urologic oncology.

[78]  William Ulma,et al.  Technical Considerations in Remote LIMS Access via the World Wide Web , 2005, Journal of automated methods & management in chemistry.

[79]  J. Vaught,et al.  Towards norms for accreditation of biobanks for human health and medical research: compilation of existing guidelines into an ISO certification/accreditation norm‐compatible format , 2007 .

[80]  Virgilia Macias,et al.  The Cooperative Prostate Cancer Tissue Resource , 2004, Clinical Cancer Research.

[81]  Eric Sampson,et al.  DNA Banking for Epidemiologic Studies: A Review of Current Practices , 2002, Epidemiology.